After finishing at $12.37 in the prior trading day, NeuroPace Inc (NASDAQ: NPCE) closed at $12.70, up 2.67%. In other words, the price has increased by $+0.33 from its previous closing price. On the day, 573583 shares were traded. NPCE stock price reached its highest trading level at $12.84 during the session, while it also had its lowest trading level at $12.40.
Ratios:
Our goal is to gain a better understanding of NPCE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.02 and its Current Ratio is at 5.71. In the meantime, Its Debt-to-Equity ratio is 3.51 whereas as Long-Term Debt/Eq ratio is at 3.43.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on March 14, 2024, Upgraded its rating to Overweight and sets its target price to $20 from $16 previously.
On January 30, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $22.
On November 10, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $11.Cantor Fitzgerald initiated its Overweight rating on November 10, 2023, with a $11 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 05 ’24 when Morrell Martha sold 3,446 shares for $15.17 per share. The transaction valued at 52,278 led to the insider holds 77,762 shares of the business.
Morrell Martha sold 14,143 shares of NPCE for $213,122 on Feb 02 ’24. The Chief Medical Officer now owns 81,208 shares after completing the transaction at $15.07 per share. On Feb 01 ’24, another insider, Morrell Martha, who serves as the Chief Medical Officer of the company, sold 663 shares for $15.04 each. As a result, the insider received 9,971 and left with 95,351 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NPCE now has a Market Capitalization of 359.69M and an Enterprise Value of 365.63M. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.50 while its Price-to-Book (P/B) ratio in mrq is 17.11. Its current Enterprise Value per Revenue stands at 5.59 whereas that against EBITDA is -16.01.
Stock Price History:
Over the past 52 weeks, NPCE has reached a high of $18.15, while it has fallen to a 52-week low of $3.80. The 50-Day Moving Average of the stock is 14.77, while the 200-Day Moving Average is calculated to be 9.12.
Shares Statistics:
The stock has traded on average 91.53K shares per day over the past 3-months and 60.93k shares per day over the last 10 days, according to various share statistics. A total of 27.82M shares are outstanding, with a floating share count of 11.76M. Insiders hold about 58.51% of the company’s shares, while institutions hold 30.65% stake in the company. Shares short for NPCE as of Mar 15, 2024 were 30.93k with a Short Ratio of 0.34, compared to 62.72k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.11% and a Short% of Float of 0.23%.
Earnings Estimates
Its stock is currently analyzed by 6 different market analysts. On average, analysts expect EPS of -$0.32 for the current quarter, with a high estimate of -$0.26 and a low estimate of -$0.38, while EPS last year was -$0.41. The consensus estimate for the next quarter is -$0.3, with high estimates of -$0.27 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$1.07 and -$1.23 for the fiscal current year, implying an average EPS of -$1.16. EPS for the following year is -$1.02, with 6 analysts recommending between -$0.5 and -$1.25.
Revenue Estimates
6 analysts predict $17.3M in revenue for the current quarter. It ranges from a high estimate of $19.05M to a low estimate of $16M. As of the current estimate, NeuroPace Inc’s year-ago sales were $14.47M, an estimated increase of 19.50% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $18.19M, an increase of 44.10% over than the figure of $19.50% in the same quarter last year. There is a high estimate of $18.88M for the next quarter, whereas the lowest estimate is $17.3M.
A total of 7 analysts have provided revenue estimates for NPCE’s current fiscal year. The highest revenue estimate was $76.6M, while the lowest revenue estimate was $73M, resulting in an average revenue estimate of $75.2M. In the same quarter a year ago, actual revenue was $65.42M, up 14.90% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $88.39M in the next fiscal year. The high estimate is $92.1M and the low estimate is $83.3M. The average revenue growth estimate for next year is up 17.50% from the average revenue estimate for this year.
